Huang Priscilla, Supan Olivia, Pak Cecilia L, Mehta Rahul C, Makino Elizabeth T
Allergan Aesthetics, an AbbVie Company, Irvine, California, USA.
SGS Stephens Inc., Richardson, Texas, USA.
J Cosmet Dermatol. 2025 Jan;24(1):e16568. doi: 10.1111/jocd.16568. Epub 2024 Sep 20.
The SkinMedica Acne Treatment Platform (SM Regimen) was formulated to treat acne without overdrying the skin. We evaluated efficacy and tolerability of the SM Regimen (including a novel 1% salicylic acid Acne Clarifying Cleanser and 2% salicylic acid Acne Treatment Lotion) versus a prescription formulation (Rx Regimen; including adapalene 0.1%/benzoyl peroxide 2.5%) in a diverse population of adults with mild to moderate facial acne.
This single-center, double-blind, randomized study enrolled adults (18-45 years) with Fitzpatrick skin types (FST) I-VI. SM Regimen or Rx Regimen was applied topically to the entire face for 12 weeks. Assessments were conducted at 24 and 48 h and 4, 8, and 12 weeks.
Subjects (SM Regimen, n = 31; Rx Regimen, n = 23) were primarily female (90.7%) with mean age of 28.6 years; 53.8% had FST IV-VI. Efficacy was comparable between regimens. The SM regimen resulted in significant improvements versus baseline in mean Investigator's Global Assessment of acne severity from 48 h through week 12 (p ≤ 0.001), as well as significant and sustained improvements from baseline in total acne lesion count, global postinflammatory hyperpigmentation/postinflammatory erythema, and oiliness. The SM Regimen was well tolerated at all time points, with mean scores below mild for all parameters; the Rx Regimen caused significantly more tightness/dry feeling at week 4 versus SM Regimen (p = 0.008). Subjects (> 96%) reported high satisfaction with the SM Regimen at all time points.
The SM Regimen reduced acne severity and skin oiliness, evening out skin tone without overdrying or irritating the skin.
SkinMedica痤疮治疗平台(SM方案)旨在治疗痤疮,同时避免皮肤过度干燥。我们在不同的轻至中度面部痤疮成年人群中,评估了SM方案(包括新型1%水杨酸痤疮清洁洁面乳和2%水杨酸痤疮治疗乳液)与一种处方制剂(Rx方案;包括0.1%阿达帕林/2.5%过氧化苯甲酰)的疗效和耐受性。
这项单中心、双盲、随机研究纳入了年龄在18至45岁、Fitzpatrick皮肤类型(FST)为I - VI型的成年人。将SM方案或Rx方案局部应用于整个面部,持续12周。在24小时和48小时以及4周、8周和12周进行评估。
受试者(SM方案组,n = 31;Rx方案组,n = 23)主要为女性(90.7%),平均年龄28.6岁;53.8%的受试者FST为IV - VI型。两种方案的疗效相当。从48小时到第12周,SM方案在平均研究者对痤疮严重程度的整体评估方面相对于基线有显著改善(p≤0.001),在总痤疮皮损计数、整体炎症后色素沉着/炎症后红斑以及油性方面相对于基线也有显著且持续的改善。SM方案在所有时间点耐受性良好,所有参数的平均评分均低于轻度;与SM方案相比,Rx方案在第4周时导致的紧绷感/干燥感明显更多(p = 0.008)。在所有时间点,超过96%的受试者对SM方案表示高度满意。
SM方案降低了痤疮严重程度和皮肤油性,使肤色均匀,同时不会使皮肤过度干燥或产生刺激。